Cargando…
Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
Tuberous sclerosis complex (TSC) is a relatively rare genetic disorder, affecting one in 6,000 births. Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, which have been previously used to prevent solid organ transplant rejection, augment anticancer treatment regimens, and prevent...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003595/ https://www.ncbi.nlm.nih.gov/pubmed/27601910 http://dx.doi.org/10.2147/NDT.S91248 |